GlassScriptPhysician profile
William K Rosen
NPI 1437240520
$2,101.65
in general payments reported to CMS, 2019-2025
25 companies · $1,087 in 2025
The $1,087 reported for 2025 was more than what 90% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
See the full distribution for Geriatric Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.73 · 2022: $75.73 · 2023: $444 · 2024: $419 · 2025: $1,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,949.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $310.28 | 2024-2025 | |
| Novo Nordisk INC | $274.53 | 2023-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $239.95 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Neurocrine Biosciences, INC. | $203.44 | 2023-2024 | Ingrezza, Ongentys |
| Abbott Laboratories | $192.10 | 2023-2025 | Freestyle Libre |
| Lilly USA, LLC | $146.30 | 2024-2025 | Kisunla, Zepbound, Jardiance |
| Pfizer INC. | $104.65 | 2023-2025 | |
| Abiomed | $75.73 | 2022 | |
| Novartis Pharmaceuticals Corporation | $61.60 | 2024-2025 | |
| Mylan Specialty L.P. | $58.37 | 2023-2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $50.68 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $50.00 | 2019 | |
| Dexcom, INC. | $48.15 | 2023-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $46.01 | 2023-2025 | Repatha, Otezla |
| Globus Medical, INC. | $37.03 | 2025 | Senza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $29.80 | 2025 | |
| Sunovion Pharmaceuticals INC. | $26.73 | 2019 | |
| Sumitomo Pharma America, INC. | $22.99 | 2024 | Gemtesa |
| Radius Health, INC. | $20.80 | 2023 | Tymlos |
| Collegium Pharmaceutical, INC. | $20.69 | 2024 | Belbuca |
| Phathom Pharmaceuticals, INC. | $18.96 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.49 | 2025 | Xifaxan |
| Viatris Specialty LLC | $16.45 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $14.12 | 2023 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.80 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.